LivaNova PLC Ordinary Shares (LIVN)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

LivaNova is a medical-device business with cardiopulmonary and neuromodulation segments. I look first at consistency, and here it is mixed. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $390.6 million and net income $108.6 million, with diluted EPS of $1.93. But in fiscal year 2025, the year ended 2025-12-31, the company reported a net loss of $242.5 million and diluted EPS of -$4.45, after net income of $63.2 million in fiscal year 2024 and $17.5 million in fiscal year 2023. That fits FairStock's Lynch category of TURNAROUND: a loss in the latest year after earlier profits. The balance sheet is not stretched—FairStock calculates debt-to-equity of 0.27 and trailing free cash flow of $148.3 million, a 3.5% FCF yield—but return on capital employed is only 5.04%, so the business does not yet earn exceptional returns. The moat is narrow at best: device and therapy businesses can have switching costs, but ROCE and the loss year argue against wide pricing power. Valuation looks full. At the $76.37 close on 2026-10-13, FairStock's P/E is 22.53, P/B 3.17, EV/EBITDA 19.4, and Graham Number is $42.85, implying a -78.23% margin of safety. Piotroski is 7/9, yet Altman Z is 1.74 and the FairStock Score is 47/100. I would need sustained profits and better capital returns before calling this a bargain.

In plain English: LivaNova makes medical devices used in heart-lung procedures and in nerve stimulation. The latest full year showed a loss after earlier profits, though recent quarters were profitable and cash flow is positive. At the recent share price, the stock looks expensive compared with its accounting value and the cash profits it has produced.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer